ASN 51
Alternative Names: ASN-51Latest Information Update: 29 Mar 2024
At a glance
- Originator Asceneuron
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Hexosaminidase C inhibitors; Muscarinic M1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease; Parkinson's disease; Unspecified
Most Recent Events
- 26 Mar 2024 Asceneuron plans a phase II trial for Alzheimer's disease in the second half of 2024 (PO)
- 22 Feb 2024 Phase-I clinical trials in Unspecified (In volunteers) in Netherlands (PO) (NCT06232109)
- 22 Jan 2024 Asceneuron plans a phase I Drug Drug Interaction trial (In volunteers) in Netherlands (PO) in February 2024 (NCT06232109)